戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 syphilis serology, including four (36%) with neurosyphilis.
2 re likely to have advanced HIV-1 disease and neurosyphilis.
3 erred by their providers due to concerns for neurosyphilis.
4 eatment and may be more likely to experience neurosyphilis.
5 d immune impairment may increase the risk of neurosyphilis.
6 um RPR titer helps predict the likelihood of neurosyphilis.
7 isk for neuroinvasion and, thus, at risk for neurosyphilis.
8              Sixty-five subjects (20.1%) had neurosyphilis.
9 he cerebrospinal fluid to exclude associated neurosyphilis.
10 ting spinal fluids of patients with possible neurosyphilis.
11                            Six (5%) had late neurosyphilis.
12 L tests, 2 patients were diagnosed as having neurosyphilis.
13  this test in the diagnosis and treatment of neurosyphilis.
14 c and clinical responses after treatment for neurosyphilis.
15 syphilis serology, including four (36%) with neurosyphilis.
16  presentations, diagnosis, and management of neurosyphilis.
17 with patients with definitive or presumptive neurosyphilis.
18 cluded as their treatment is the same as for neurosyphilis.
19 ease has been accompanied by a resurgence of neurosyphilis.
20 ction, and attempt to estimate the burden of neurosyphilis.
21 treatment, and follow-up of individuals with neurosyphilis.
22 PR) titer > or =1 : 32 increased the odds of neurosyphilis 10.85-fold in human immunodeficiency virus
23                                              Neurosyphilis, a complication of syphilis, can occur at
24 inical features of early and late (tertiary) neurosyphilis and characterize the clinical significance
25 iew preferred and alternative treatments for neurosyphilis and evidence for their use, including evid
26                                   Reports of neurosyphilis and invasion of cerebrospinal fluid by Tre
27 urological signs or symptoms consistent with neurosyphilis, and asymptomatic persons whose serologica
28 best way to identify individuals at risk for neurosyphilis, and the justification for identifying and
29                  None had clinically evident neurosyphilis, and the rate of detection of T. pallidum
30                         As manifestations of neurosyphilis are famously varied, a high index of suspi
31 nally, improved criteria and diagnostics for neurosyphilis (as well as ocular and otic syphilis) are
32                The aOR of laboratory-defined neurosyphilis at the index episode was also significantl
33                                   The aOR of neurosyphilis at the index episode was also significantl
34                                  The aOR for neurosyphilis at the index episode was also significantl
35 gy, clinical manifestations and treatment of neurosyphilis, beginning with information from the pre-p
36 This review sets the stage for understanding neurosyphilis by briefly summarizing the clinical and la
37         Our study characterizes a cluster of neurosyphilis cases among HIV-1-infected individuals in
38         Our study characterizes a cluster of neurosyphilis cases among people with human immunodefici
39                We tested the hypothesis that neurosyphilis causes cognitive impairment in HIV by ampl
40                             For diagnosis of neurosyphilis, cerebrospinal fluid (CSF) TP-PA has simil
41  of 42 patients infected with type 14d/f had neurosyphilis compared with 10 (24%) of 41 patients infe
42 dition to a reactive CSF-VDRL, the number of neurosyphilis diagnoses would have increased from 47 to
43 (CSF-TPHA) titer of >/=1:640 is specific for neurosyphilis diagnosis.
44  count may indicate continued imprecision in neurosyphilis diagnostic criteria due to HIV-related CSF
45 counts may indicate continued imprecision in neurosyphilis diagnostic criteria, due to HIV-related CS
46 te the epidemiology and clinical spectrum of neurosyphilis in a population with high rates of coexist
47 sults, no evidence was found for undiagnosed neurosyphilis in HIV-infected patients.
48 microL conferred 3.10-fold increased odds of neurosyphilis in HIV-infected subjects.
49 on for identifying and treating asymptomatic neurosyphilis in selected situations.
50 ze the clinical significance of asymptomatic neurosyphilis in the antibiotic era.
51         Early syphilis increased the odds of neurosyphilis in univariate but not multivariate analyse
52                  Measuring the prevalence of neurosyphilis is challenging, and there are limited data
53  cerebrospinal fluid examination to diagnose neurosyphilis is recommended in persons diagnosed with t
54                                              Neurosyphilis may augment HIV-associated CNS inflammatio
55                Establishing the diagnosis of neurosyphilis may be particularly difficult in human imm
56 e treatment with penicillin, particularly in neurosyphilis, neonatal syphilis, and pregnancy, highlig
57 uring bacterial infection, but their role in neurosyphilis (NS) pathogenesis and response has not yet
58  biological characteristics of patients with neurosyphilis (NS), and we assessed the diagnostic value
59 nt, or unknown duration; tertiary as well as neurosyphilis, ocular syphilis, and otic syphilis).
60 sting and treatment for cases concerning for neurosyphilis/ocular syphilis was obtained from provider
61 treated for and/or clinically diagnosed with neurosyphilis/ocular syphilis.
62 al fluid, of which 21 (95%) were treated for neurosyphilis/ocular syphilis.
63 ntreponemal (VDRL) titers (median, 1:128) at neurosyphilis presentation.
64 ular syphilis should be treated according to neurosyphilis regimens and should receive cerebrospinal
65                                              Neurosyphilis remains an important and highly morbid neu
66 re likely to have advanced HIV-1 disease and neurosyphilis, supported by phylogenetic and network ana
67 ht (33%) presented with an early symptomatic neurosyphilis syndrome.
68 es were identified more frequently than late neurosyphilis syndromes.
69 and HIV RNA (727 vs. 50 c/mL) were higher in neurosyphilis than in uncomplicated syphilis (P </= .001
70 In the current antiretroviral treatment era, neurosyphilis treatment outcome is not different for Pen
71 In the current antiretroviral treatment era, neurosyphilis treatment outcomes are not different for P
72                               Data comparing neurosyphilis treatment regimens are limited.
73                                              Neurosyphilis was defined as (i) a reactive CSF Venereal
74                                              Neurosyphilis was defined as a cerebrospinal fluid (CSF)
75                                              Neurosyphilis was defined as detection of Treponema pall
76                                              Neurosyphilis was defined by a newly reactive cerebrospi
77  to the findings from the preantibiotic era, neurosyphilis was identified in young patients most ofte
78                                         When neurosyphilis was more stringently defined as a reactive
79                                         When neurosyphilis was more stringently defined as a reactive
80           Similar results were obtained when neurosyphilis was more stringently defined as a reactive
81                                              Neurosyphilis was not related to low MAT scores.
82  cerebrospinal fluid VDRL; 117 patients with neurosyphilis were identified.
83 0 may be useful in identifying patients with neurosyphilis when CSF-VDRL is nonreactive.
84                                              Neurosyphilis, which can occur at any stage, can lead to
85  of the pathogenesis of JHR in patients with neurosyphilis who develop transient neurologic signs.
86 bjects (n=326) with syphilis but no previous neurosyphilis who met 1993 Centers for Disease Control a
87       Ocular syphilis should be treated like neurosyphilis, with daily intravenous or intramuscular p